| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ef2e9f5ce8630d9b282043b8d060caff |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-498
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-498
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 |
| filingDate |
2013-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28d4bec3aeee77d2cfe14eff50748a3a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81c90ae3dcf2d42e26a4cecc3e4e7511
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51c6f64b4e3aeecefc86608fab144dba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac2fac352f94243591dd99d7c0d854d6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1f72877fb6dba54b1ffdb14447e540b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb6de564e0b42ed785cf3e9076731fd8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1baa0fc13d8d2d4b7b8d158e2383c162 |
| publicationDate |
2013-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2013236526-A1 |
| titleOfInvention |
Sustained Release Intraocular Implants and Methods for Preventing Retinal Dysfunction |
| abstract |
Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11400070-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019213358-A1 |
| priorityDate |
2004-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |